European Journal of Clinical Pharmacology

, Volume 33, Issue 1, pp 77–79 | Cite as

Methylergometrine antagonizes 5 HT in the temporal artery

  • P. Tfelt-Hansen
  • I. Jansen
  • L. Edvinsson
Short Communications


Methylergometrine, the main metabolite of methysergide, has 40-times greater 5 HT antagonistic potency than methysergide in isolated segments of human temporal artery. It is suggested that methylergometrine is the “active” drug when methysergide is used in migraine prophylaxis, and that the two compounds should be compared in prophylactic trials in migraine.

Key words

methysergide methylergometrine 5-HT antagonism migraine therapy human temporal artery 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Shekelle RB, Ostfeld AM (1964) Methysergide in the migraine syndrome. Clin Pharmacol Ther 5: 201–204PubMedGoogle Scholar
  2. 2.
    Fozard JR (1982) Basic mechanisms of antimigraine drugs. In: Critchley M, Friedman AP, Sicuteri F, Gorini S (eds) Advances in neurology. Raven Press, New York, pp 295–307Google Scholar
  3. 3.
    Biachine JR (1968) Metabolism of methysergide (MS) in the rabbit and man. Fed Proc 27: 238Google Scholar
  4. 4.
    Müller-Schweinitzer E, Weidman H (1978) Basic pharmacological properties. In: Berde B, Schild HO (eds) Ergot alkaloids and related compounds. Handbook of experimental pharmacology 49. Springer, Berlin Heidelberg New York, pp 87–232Google Scholar
  5. 5.
    Bredberg U, Eyjolfsdottir GS, Paalzow L, Tfelt-Hansen P, Tfelt-Hansen V (1986) Pharmacokinetics of methysergide and its metabolite methylergometrine in man. Eur J Clin Pharmacol 30: 75–77PubMedCrossRefGoogle Scholar
  6. 6.
    Müller-Schweinitzer E, Tapparelli C (1986) Methylergometrine, an active metabolite of methysergide. Cephalalgia 6: 35–41PubMedCrossRefGoogle Scholar
  7. 7.
    Skärby T, Tfelt-Hansen P, Gjerris F, Edvinsson L, Olesen J (1982) Characterization of 5-hydroxytryptamine receptors in human temporal arteries: Comparison between migraine sufferers and non-sufferers. Ann Neurol 12: 272–277PubMedCrossRefGoogle Scholar
  8. 8.
    Van den Brink (1977) General theory of drug receptor interactions. In: Van Rossum JM (ed) Kinetics of drug action. Springer, Berlin Heidelberg New York, pp 247–249Google Scholar
  9. 9.
    Graham JR, Wolff HG (1938) Mechanism of migraine head-ache and the action of ergotamine. Arch Neurol Psychiatr 39: 737–763Google Scholar
  10. 10.
    Saxena PR (1974) Selective vasoconstriction in the carotid vascular bed by methysergide: Possible relevance to its antimigraine effect. Eur J Pharmacol 27: 99–105PubMedCrossRefGoogle Scholar
  11. 11.
    Mylechrane EJ, Spira PJ, Misbach J, Duckworth JW, Lance JW (1978) Effects of methysergide, pizotifen and ergotamine in the monkey cranial circulation. Eur J Pharmacol 48: 1–9CrossRefGoogle Scholar
  12. 12.
    Spierings ELH, Saxena PR (1980) Antimigraine drugs and cranial arteriovenous shunting in the cat. Neurology 30: 696–701PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • P. Tfelt-Hansen
    • 1
  • I. Jansen
    • 2
  • L. Edvinsson
    • 3
  1. 1.Department of NeurologyRigshospitaletCopenhagenDenmark
  2. 2.Department of Experimental ResearchMalmö General HospitalMalmöSweden
  3. 3.Department of Clinical Pharmacology and Internal MedicineUniversity HospitalLundSweden

Personalised recommendations